Introduction {#Sec1}
============

Lung cancer is the leading cause of cancer related mortality, accounting for over one million deaths worldwide annually \[[@CR1]\]. Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death worldwide, with an estimated prevalence of 4--10% \[[@CR2]\]. COPD is characterised by chronic inflammation of the lower airways and similar to 90% of lung cancer cases is caused by cigarette smoking \[[@CR2]\]. The presence of COPD can increase the risk of lung cancer by 4.5-fold \[[@CR3]\] and among smokers with COPD, inflammation persists and lung function continues to deteriorate even following smoking cessation \[[@CR4]\].

Some animal models have suggested that nontypeable (i.e. uncapsulated) *Haemophilus influenzae* (NTHi) may play a causal role for a COPD-like airway inflammation and in lung cancer promotion \[[@CR5], [@CR6]\]. Exposure of genetically modified mice to NTHi and the most potent cigarette smoke carcinogen (NNK), resulted in a 2.2-fold increase in the number of tumours identified \[[@CR5]\]. NTHi presence may induce inflammation which may subsequently promote lung carcinogenesis. NTHi can be found in the lower respiratory tract of 30% - 50% of COPD patients \[[@CR7]\]. To the best of our knowledge, there have not been any studies specifically evaluating the prevalence of NTHi in lung cancer patients compared with COPD patients without lung cancer. The aims of this study are to measure and compare the presence of NTHi in the bronchial airway and NTHi specific antibodies in the blood of lung cancer and COPD patients.

Methods {#Sec2}
=======

Study sample {#Sec3}
------------

Consecutive adult (age ≥ 18 years old) outpatients were considered for the study. All participating subjects provided written informed consent. The study was approved by the local Human Research Ethics Committee (HREC/14/QPCH/75; MSC/02/14/HREC). Power calculations were performed to determine the minimum sample size of patients with lung cancer, COPD and controls with an alpha value of 0.05 and power of 80%. Based on the reported incidence of NTHi in bronchoscopy \[[@CR8]\] and sputum \[[@CR9]\], the minimum sample size to detect NTHi among the groups (i.e primary outcome at an estimated clinically meaningful effect) at a power of 0.05 and 80% was 11 patients with lung cancer, 11 patients with COPD and 7 control patients. Power calculations determined that a sample size of 60 patients would provide a power coefficient of 0.96.

Consecutive patients who were required to undergo a bronchoscopy procedure were considered for the study. Patients were excluded if they were below 18 years old, unable to provide written consent, if the bronchoscopy procedure was being performed as a medical emergency, or if the procedure was performed on the weekend or outside usual working hours (8 am-5 pm). All patients scheduled to undergo bronchoscopy were given standardized written and verbal information about the research study. Patients who were experiencing a lower respiratory tract infection or COPD exacerbation were excluded from the bronchoscopy procedure and hence the study as well. Consenting patients were recruited to the study. Contact was made with eligible participants between November 2014 and September 2015.

Biological samples {#Sec4}
------------------

All three groups of patients had bronchial wash and serum samples collected. The bronchial wash samples consisted of two aliquots of at least 10 mls of sterile normal saline obtained from the right middle lobe. One aliquot of the bronchial wash was sent for routine bacterial culture at the Clinical Microbiology Department, Queensland Pathology, Gold Coast University Hospital. The second aliquot was sent for NTHi polymerase chain reaction (PCR) analysis. Briefly, DNA was extracted from bronchial wash samples using a salt and alcohol precipitation method \[[@CR10]\]. A unique primer and probe set was used to detect the fucP locus of the NTHi genome as described previously \[[@CR11]\]. A second reaction for the detection of the *bexA* locus, characteristic of typeable haemophilus strains, was also performed as described previously \[[@CR12]\]. Samples were classified as NTHi positive, based on the detection of the *fucP* locus in the absence of the *bexA* locus.

Blood was collected by venepuncture immediately before bronchoscopy. The blood was clotted and the serum separated by centrifugation. Total IgE concentrations were determined using commercially available enzyme linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (Affymetrix eBioscience, San Diego, CA, USA). NTHi-specific IgG antibodies to both total NTHi lysate and an outer membrane protein (OMP) preparation were measured in the serum using commercially available enzyme linked immunosorbent assay reagents (ELISA; Affymetrix eBioscience, San Diego, CA, USA). Briefly, 96-well Nunc Maxisorp immunoassay plates (Affymetrix eBioscience, San Diego, CA, USA) were coated overnight with 100 ng of either complete lysate or OMP, in a carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3) prepared as described previously \[[@CR13]\]. Assays were then completed using standardised protocols as per manufacturer's instructions (Affymetrix eBioscience, San Diego, CA, USA)..

All statistical analyses were performed using SPSS (Version 19, SPSS Inc., Chicago, USA). Kurtosis and skewness evaluation was performed to determine if measurements had normal distribution. Normally distributed variables are reported as means and standard deviations. Comparative analysis of normally distributed data and binomial data was performed using one-way ANOVA and Chi-Square test, respectively. Statistical significance was accepted at *p* \< 0.05.

Results {#Sec5}
=======

Subjects {#Sec6}
--------

After exclusions, sixty subjects provided written consent and were recruited for the study. In the study cohort, 20 patients had been diagnosed with lung cancer (confirmed pathological diagnosis of lung cancer), 27 with COPD (Spirometry confirmed diagnosis of COPD AND chest x-ray or CT within the preceding 3 months to exclude lung cancer diagnosis) and 13 subjects were the control group (Spirometry and imaging excluded diagnosis of lung cancer and/or COPD). Characteristics of the groups are shown in Table [1](#Tab1){ref-type="table"}. The three groups were matched for age and gender. The prevalence of never smokers was highest in the Control patients (69%) and lowest in the Lung Cancer patients (5%). Lung function measurements demonstrated that the FEV~1~ (mean age ± SD) was significantly different between the three groups of patients (Lung Cancer patients: 67 ± 17; COPD patients: 68 ± 25; Control patients: 91 ± 20, *p* = 0.007). There was no difference in the frequency of diagnosis of asthma across the three groups of patients (*p* = 0.385). With regards to respiratory medications, there were no differences across the groups for inhaled corticosteroids (*p* = 0.290), inhaled bronchodilators (*p* = 0.241) and systemic corticosteroids (*p* = 0.228). No patients were receiving systemic antibiotics at the time of the study.Table 1Characteristics of Study SubjectsCharacteristicsLung CancerCOPDControlNumber of subjects202713Age (mean ± SD)67 ± 1068 ± 958 ± 15Males, n (%)10 (50)17 (63)6 (46)Asthma diagnosis, n (%)3 (15)5 (19)3 (23)Spirometry (mean ± SD) FEV~1~ (% of predicted)67 ± 1768 ± 2591 ± 20 FVC (% of predicted)86 ± 1288 ± 2491 ± 20 FEV~1~/FVC59 ± 1256 ± 1278 ± 6Smoking status, n(%) Current smoker13 (65)7 (26)0 Former smoker6 (30)18 (67)4 (31) Never smoker1 (5)2 (7)9 (69)Pack/years in smokers (mean ± SD)44 ± 1843 ± 288 ± 15Treatment at time of review, n (%) Antimicrobial therapy000 Inhaled corticosteroid therapy5 (25)11 (41)4 (31) Inhaled bronchodilator therapy6 (30)13 (48)4 (31) Systemic corticosteroid therapy1 (5)01 (7)*Abbreviations:FEV*~*1*~ Forced Expiratory Volume in one second, *FVC* Forced Vital Capacity, *NTHi* Non-Typeable Haemophilus

NTHi identification {#Sec7}
-------------------

Using the PCR method, NTHi was identified in the bronchial wash samples of 20% of Lung Cancer patients, 22% of COPD patients and 15% of Control patients (Table [2](#Tab2){ref-type="table"}). Conversely, using the culture method, NTHi was only identified the bronchial wash samples of 10% of Lung Cancer patients, 22% of COPD patients and 8% of Control patients (*p* = 0.36). There was a strong correlation between the NTHi PCR and culture results (r^2^ = 0.56, *p* \< 0.001).Table 2Biomarkers in the Lung cancer, COPD and Control GroupsBiomarkerLung CancerCOPDControl*N* = 20*N* = 27*N* = 13Serum, Total IgG ng/ml (mean ± SE)6.87 ± 0.38\*\*5.36 ± 0.395.97 ± 0.51 Total IgE, ng/ml (median ± IQR)243 ± (181.3--305.5)†, \*\*172.5 ± (95.5--297.8)\*91.0 ± (69.5--266.5) IgG to NTHi OMP, RU (mean ± SE)2.10 ± 0.222.02 ± 0.161.74 ± 0.24 IgG to NTHi P6, (mean ± SE)1.55 ± 0.131.62 ± 0.101.32 ± 0.07Bronchial wash (n (%) NTHi Culture positive2 (10)6 (22)1 (8) NTHi PCR positive5 (20)6 (22)2 (15)PPM Staphylococcus aureus1 Streptococcus pneumoniae1 Pseudomonas aeruginosa2 Stenotrophomonas maltophilia1Non-PPM Atypical Mycobacterium1 Aspergillus fumigatus11 No microorganism171611\**p* \< 0.05 between COPD and controls; † *p* \< 0.05 between Lung Cancer and controls; \*\* *p* \< 0.05 between Lung Cancer and COPDPPM-Potential Pathogenic Organisms

Serum immunoglobulins {#Sec8}
---------------------

The immunoglobulin differences between the three groups in the study are provided in Table [2](#Tab2){ref-type="table"}. In patients with Lung Cancer, the levels of total IgG in serum were elevated compared to COPD patients (*p* = 0.02). The total IgE levels in Lung Cancer patients were higher than COPD patients (*p* = 0.03) and control patients (91 (69.5--266.5, *p* = 0.001) respectively. Furthermore, the only difference between COPD patients and Control patients was the total IgE (*p* = 0.001). There were no other significant differences in the serum biomarkers among the three groups of patients.

Discussion {#Sec9}
==========

In this study, we prospectively investigated the lower airways for NTHi bacteria in lung cancer, COPD and control patient groups. We also evaluated immunological biomarkers in the blood of the three patient populations. While there was no difference in the rates of identification of NTHi among the three patient populations, there were significant differences in immunological measures between groups.

Recently there has been growing awareness of the importance of NTHi in the pathophysiology of chronic lower respiratory tract inflammatory disorders, particularly COPD \[[@CR14]\]. The use of bronchial wash specimens and molecular identification techniques allowed for assessment of NTHi directly from the lower airways in the current study. Bronchial colonisation by bacteria in patients with lung cancer has previously been reported \[[@CR15]\]. Laroumagne et al. reported that bacterial bronchial colonisation can be identified in 48% of patients with lung cancer and specifically, NTHi was identified in 4.3% \[[@CR8]\]. In the current study NTHi was detected in up to 22% of collected samples. This higher rate of identification of NTHi than that previously reported may be due to use of more sensitive methods employed to detect NTHi. However, the small sample size of our study limits our ability to make any definitive inferences about NTHi bacteria identification and possible pathogenic role of this bacteria in patients with lung cancer compared to other patient groups. A pertinent challenge will be the disentanglement of COPD from lung cancer in order to determine the pathophysiological role of NTHi. Recent evidence suggests that lung cancer patients with COPD may have a different pattern of driver mutations and molecular features \[[@CR16]\]. It is hypothesised that these differences may be due to COPD specific inflammatory microenvironment and may result in epigenetic and other molecular mechanisms eventually promoting carcinogenesis \[[@CR16]\]. Future studies will need to determine if NTHi colonisation contributes to the enhancement of the COPD related inflammation in the airways and lung parenchyma.

Immunoglobulin assessments revealed significantly higher total IgE and IgG concentrations in lung cancer patients, however the relevance of these observations is not clear. A possible association between allergy and cancer has been reported previously \[[@CR17], [@CR18]\], but widely replicated results are lacking with some studies reporting a negative association \[[@CR17], [@CR18]\], others showing a positive association \[[@CR19], [@CR20]\] or no general association \[[@CR21]\]. Studies that have specifically evaluated IgE in patients with lung cancer have found a positive association with not only lung cancer diagnosis \[[@CR22]\] but also increased mortality in females \[[@CR23]\]. A possible explanation for this phenomenon is thought to be that the lung is directly exposed to the noxious stimuli which can be both allergens and carcinogens. This direct exposure induces excessive inflammation in allergic subjects which in turn may promote tumour development \[[@CR24]\]. It is also possible that the elevated IgE levels may be an immunological response to infection. Indeed, there is now emerging data to suggest that the total microbial load is higher and considerably varied in lung cancer patients compared to controls \[[@CR25]\]. However, it is also possible that IgE is an epi-phenomenon in patients with underlying reactive airways disease, i.e. asthma. While we obtained information about a diagnosis of asthma, we did not systematically exclude other causes of elevated IgE. Furthermore, the diagnosis of asthma was a clinical diagnosis rather than subjecting every patient to a thorough clinical and pulmonary function laboratory assessment for asthma. But there are several possible causes of an elevated IgE, such as primary immunodeficiency syndromes, infections, inflammatory disorders and malignancy, and it was beyond the scope of this study to systematically exclude other possible causes of an elevated IgE. This should be explored in future studies, where the patient populations should be controlled for (at least) the common causes of an elevated IgE.

Our study was a pilot study with a relatively small sample size. Also the results of our study were not corrected for age, which may be relevant since our cohort of patients were older than the controls. It is possible that a trend for higher prevalence of NTHi in patients with lung cancer may not have been identified in a small subgroup analysis. A larger prospective study of patients may need to be undertaken to address this limitation. Our study is an observational cohort study and consequentially there was no blinding of the study subjects to the study investigators. Future research may need to be designed such that there is adequate blinding of the study investigators and be performed across multiple centres to ensure that the results obtained are not only robust but also reproducible.

Conclusions {#Sec10}
===========

Our pilot study found that the NTHi identification in the lower airways of patients with Lung Cancer is not different from patients with COPD and Controls. Further research on a larger sample size and other biological samples may be required to better characterize the prevalence NTHi in the lower airways of patients with lung cancer compared to patients with COPD and healthy individuals. It is important to continue to gain more information about NTHi in patients with lung cancer since it may contribute to the growing body of knowledge about the different mechanisms that result in lung carcinogenesis.
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